Title:Differentiation of Pancreatic Beta Cells: Dual Acting of Inflammatory Factors
Volume: 19
Issue: 6
Author(s): Faeze Shahedi, Arron Munggela Foma, Azam Mahmoudi-Aznaveh, Mohammad Ali Mazlomi, Zahra Azizi*Mohammad Reza Khorramizadeh*
Affiliation:
- Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Biosensor Research Center, Endocrinology and Metabolism Molecular-
Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
Keywords:
Autoimmunity, leukocytes, pathogens, pancreatic beta cell, type 1 diabetes, cytokines.
Abstract: In the past decades, scientists have made outstanding efforts to treat diabetes. However, diabetes
treatment is still far from satisfactory due to the complex nature of the disease and the challenges encountered
in resolving it. Inflammatory factors are key regulators of the immune system's response to
pathological insults, organ neogenesis, rejuvenation of novel cells to replace injured cells and overwhelming
disease conditions. Currently, the available treatments for type 1 diabetes include daily insulin injection,
pancreatic beta cell or tissue transplantation, and gene therapy. Cell therapy, exploiting differentiation,
and reprogramming various types of cells to generate pancreatic insulin-producing cells are novel
approaches for the treatment of type 1 diabetes. A better understanding of the inflammatory pathways
offers valuable and improved therapeutic options to provide more advanced and better treatments for
diabetes. In this review, we investigated different types of inflammatory factors that participate in the
pathogenesis of type 1 diabetes, their possible dual impacts on the differentiation, reprogramming, and
fusion of other stem cell lines into pancreatic insulin-producing beta cells, and the possibility of applying
these factors to improve the treatment of this disease.
